Skin-derived tumor specific T cells predict clinical outcome in dendritic cell vaccination studies in both stage III and IV melanoma patients

Eitemau Tebyg

• Dendritic cell vaccination and immune monitoring
  gan: Aarntzen, E. H. J. G., et al.
  Cyhoeddwyd: (2008)
• Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients
  gan: Boudewijns, Steve, et al.
  Cyhoeddwyd: (2016)
• Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination
  gan: Bol, Kalijn F, et al.
  Cyhoeddwyd: (2015)
• Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients
  gan: Bol, Kalijn, et al.
  Cyhoeddwyd: (2015)
• Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4(+) T cells after FcγRII-mediated uptake
  gan: Benitez-Ribas, Daniel, et al.
  Cyhoeddwyd: (2006)